Tecartus (brexucabtagene autoleucel) for the Treatment of Mantle Cell Lymphoma (MCL)

Image 2-Tecartus
Tecartus™ is an autologous, anti-CD19 CAR T cell therapy. Credit: Kite, a Gilead Company.